Changchun Bcht Biotechnology (688276.SH): Approval Granted for Clinical Trial Application of Type II Herpes Simplex Virus mRNA Vaccine

Changchun Bcht Biotechnology (688276.SH) announced that the company has recently received the "Notification of Approval for Drug Clinical Trials" issued by the National Medical Products Administration, allowing LVRNA101 to conduct clinical trials for the prevention of genital herpes caused by Type II herpes simplex virus infection. The LVRNA101 approved by the company is a Type II herpes simplex virus mRNA vaccine (HSV-2 vaccine). As of now, there are no similar vaccine products successfully developed and marketed globally. If the company's Type II herpes simplex virus mRNA vaccine can be successfully developed, it will further enrich the company's product pipeline and better meet market demands.